Immune Pharmaceuticals raises $11.7m on Nasdaq
US company EndoChoice, which also closed a $43 million financing round, will market products that Peer will develop in Israel.
Israeli endoscopic start-up Peer Medical Ltd. has merged with US gastrointestinal endoscopy company EndoChoice Inc. Accelmed, run by chairman Mori Arkin and managing partner Uri Geiger is the largest investor in Peer Medical.
According to EndoChoice, Sequoia Capital will lead a $43 million financing round in the merged company. Given the size of the investment and the previous transactions by the two competing companies, it is possible to estimate that Sequoia is making the investment at a company value of several hundred million dollars.
EndoChoice and Peer Medical did not disclose the relative proportions of the merger. EndoChoice is presumably the larger partner, but Peer Medical's shareholders will own a large stake in the merged company.
EndChoice has more than 2,500 customers in 34 countries, and will be responsible for the marketing of the two companies' products. Peer Medical will continue to function as the Israeli R&D center for both companies, and will help develop EndoChoice products.
The merger fits in with Accelmed's strategy to acquire US companies with domestic distribution networks and combine them with products from Accelmed portfolio companies. The cost of building a new distribution network can cost tens of millions of dollars and it is not worthwhile for a single product. Accelmed therefore seeks to combine products from its portfolio companies with existing distribution networks, not through the usual method of distribution agreements, but by taking over existing networks or by merging operations as in the case of Peer Medical and EndoChoice. This gives the manufacturer greater control of the marketing activity.
Accelmed is the largest shareholder in MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) as well as in start-ups Cardiapex Ltd., Cartiheal Ltd., Eximo Medical Ltd., EndoSpan Ltd., NLT Spine (Non Linear Technologies) Ltd., Pi-R Squared Ltd., and Valcare Medical Ltd.
Peer Medical has developed an endoscope to diagnose gastrointestinal polyps, which can develop into bowel cancer. Current diagnosis is based on colonoscopy, which can miss 25-40% of polyps. Peer Medicals' device provides a broader image of the bowel.
EndoChoice chairman and CEO Mark Gilreath (a former VP at Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN)) compared Peer Medical's Full Spectrum Endoscope with standard products as driving with and without a rear-view mirror, respectively. Peer Medical's product already has US Food and Drug Administration (FDA) clearance, but the company is waiting on sales until the merger is completed.
Peer Medical was founded in 2006 by CEO Avi Levy and its other founders previously founded Sightline, which was sold to Stryker Corporation (NYSE: SYK) for $140 million. Stryker subsequently closed its Israeli operations and halted development of Sightlline's product.
Levy said today, "We are thrilled that the fastest growing medtech company in the US will now be offering the world’s most innovative endoscope. We look forward to building on EndoChoice’s platform and established customer base and working together to commercialize this breakthrough technology."
Geiger said, "This is a deal that represents the vision of creating real companies. We preferred the platform model which combines Israeli technology with a US commercial platform over acquisition by a big company in the belief that the merger of the companies will created the biggest Israeli medical company in the world."
Published by Globes [online], Israel business news - www.globes-online.com - on January 6, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.